SCHEMBL130124

SCHEMBL130124

Cc1cccnc1C(C)(C)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 1/20 0.50
NOS1 P29475 1/20 0.50
NOS2 P35228 1/20 0.50
SSTR4 P31391 1/20 0.43
NPC1 O15118 3/20 0.41
RAB9A P51151 2/20 0.41
PLAU P00749 1/20 0.41
KDM4E B2RXH2 1/20 0.41
L3MBTL1 Q9Y468 3/20 0.39
MAPT P10636 1/20 0.39
HTT P42858 2/20 0.37
CYP2A6 P11509 1/20 0.37
SLC6A2 P23975 1/20 0.37
PDK2 Q15119 1/20 0.37
FDPS P14324 2/20 0.36
CYP3A4 P08684 1/20 0.36
TSHR P16473 1/20 0.36
CYP2C19 P33261 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.35
HSP90AA1 P07900 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30816293 1.00 NOS3 (0.50) NOS3NOS1NOS2SSTR4NPC1
SCHEMBL77479 0.82 NOS3 (0.48) NOS3NOS1NOS2SSTR4NPC1
SCHEMBL15192976 0.79 SSTR4 (0.39) NOS3NOS1NOS2SSTR4NPC1
SCHEMBL5038676 0.78 ALDH1A1 (0.44) KDM4EL3MBTL1HTTSLC6A2CYP3A4
SCHEMBL1332434 0.78 NOS3 (0.45) NOS3NOS1NOS2SSTR4NPC1
SCHEMBL16252854 0.78 NOS3 (0.50) NOS3NOS1NOS2SSTR4NPC1
SCHEMBL16019426 0.78 NOS3 (0.45) NOS3NOS1NOS2SSTR4NPC1
SCHEMBL129161 0.78 NOS3 (0.41) NOS3NOS1NOS2SSTR4NPC1
SCHEMBL23126660 0.77 ACSS2 (0.36) KDM4EL3MBTL1MAPTHTTCYP3A4
SCHEMBL16836001 0.77 SMN1; SMN2 (0.35) SSTR4KDM4EL3MBTL1MAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023141511-A1 POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 VANDERBILT UNIVERSITY (US) 2023-07-27 WO disclosed
US-8450319-B2 Pyrrolopyridazinone compound UBE INDUSTRIES, LTD. (JP) 2013-05-28 US disclosed
EP-1982986-B1 PYRROLOPYRIDAZINONE COMPOUND AS PDE4 INHIBITOR UBE INDUSTRIES (JP) 2012-03-07 EP disclosed
CN-101374844-A Pyrrolopyridazinone compound UBE INDUSTRIES (JP) 2009-02-25 CN disclosed
US-20090036453-A1 Pyrrolopyridazinone Compound UBE INDUSTRIES, LTD. (JP) 2009-02-05 US disclosed
EP-1982986-A1 PYRROLOPYRIDAZINONE COMPOUND Ube Industries, Ltd. (JP) 2008-10-22 EP disclosed
US-5256785-A Smoking compositions containing an oxalate flavorant-release additive PHILIP MORRIS INCORPORATED (US) 1993-10-26 US disclosed
US-5172706-A Smoking compositions containing an oxalate flavorant-release additive PHILIP MORRIS INCORPORATED (US) 1992-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090036453-A1 Pyrrolopyridazinone Compound CBR3, CBR1, CYC1 NOS3 515/4885NOS1 1066/4885NOS2 972/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.